Insider buying last 90 days
No open-market insider purchases were filed for ARWR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
This week's news centers on plozasiran, Arrowhead's RNAi therapy for severe hypertriglyceridemia. At the American Heart Association Scientific Sessions 2026, the company presented pooled data from the SHASTA-3 and SHASTA-4 trials showing sustained triglyceride reductions and a 78% reduction in acute pancreatitis events versus placebo, with a 91% reduction among patients with a history of the condition. Separately, Arrowhead refinanced its $400 million credit facility with Sixth Street, lowering borrowing costs and extending maturity to November 2031, and confirmed it will host its fiscal year-end results webcast alongside its upcoming earnings report.
Shares closed at $49.24, down 15.3% on the day and sitting well below both the 50-day average of $66.20 and the 200-day average of $71.46, with the 50-day below the 200-day. The one-month return stands at -21.5% and the three-month return at -44.8%, against a 52-week range of $37.06 to $95.49. The GekkoIndex reads 76.3, placing the stock in the Buying zone, while price sits 41.5% below Gekko Fair Value of $84.20.
Earnings are due 12 November 2026 after the close, just 81 days away, with options pricing an 8.1% move and a history of an average absolute reaction of 13.6% across prior reports, including a 43.7% move in November 2025. Seasonality over the next 20 trading days has averaged +9.2% across 5 years, rising in 2 of those years. No insider, Congress, or unusual options activity appears in the current windows, and consensus among 11 covering firms shows 10 buy ratings and 1 hold.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Arrowhead Pharmaceuticals scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
Below 50 and 200-day
Close $47.78 is below the 50-day ($63.32) and 200-day ($71.09) averages, and the 50-day is below the 200-day.
See the chart74.9, Buying
Reading 74.9 is in the Buying zone.
See the GekkoIndex39.4% below
Price is 39.4% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 81 days
Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.
See earnings+13.9% on average
From this point in the calendar, the next 20 trading days averaged +13.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Arrowhead Pharmaceuticals closed at $47.78 on Nov 13, 2026, +15.4% over the past year, inside a 52-week range of $37.06 to $95.49.
Use the left and right arrow keys to read daily values.
Put ARWR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Arrowhead Pharmaceuticals works on medicines for serious and hard-to-treat conditions, built around RNA interference technology that aims to switch off disease-causing genes. Its pipeline spans liver conditions linked to alpha-1 antitrypsin deficiency, high triglyceride levels, cholesterol-related targets, kidney cancer, lung and airway disorders, muscular dystrophy, gout and COVID-19-related pulmonary illness, with programs at stages ranging from early clinical trials to later-phase testing.
Much of its work is carried out through partnerships as well as internal research. It has agreements with Janssen Pharmaceuticals to jointly develop a set of RNAi candidates aimed at liver-related targets, and with Takeda Pharmaceuticals U.S.A. on another liver-disease therapeutic. It also contributes to programs such as a subcutaneous treatment for chronic hepatitis B, a candidate aimed at lowering apolipoprotein levels, and cardiovascular-focused therapies developed alongside outside partners, reflecting a model that combines its own science with outside collaboration.
Arrowhead Pharmaceuticals is based in Pasadena, California, and traces its founding back to 1989. Its shares are listed on the NASDAQ under the ticker ARWR.
Arrowhead Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 74.9, in the Buying zone, up 9.1 points over five sessions.
Up 9.1 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 58 | 0.0% | −2.6% | ||
| Accumulation | 229 | +0.3% | −0.1% | ||
| Neutral | 378 | +1.1% | +5.6% | ||
| Distribution | 36 | +2.5% | +12.3% | ||
| Selling | 1 | Too few readings yet | |||
Average ARWR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
Arrowhead Pharmaceuticals trades 39.4% below Gekko Fair Value of $78.84, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Arrowhead Pharmaceuticals shares are worth, recalculated every trading day.
$78.84
Gekko Fair Value, Nov 14, 2026
39.4% Undervalued
At the end of Aug 2026 the price was 18.3% below the estimate.
No open-market insider purchases were filed for Arrowhead Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ARWR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ARWR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1signal, 97% of the flagged premium in calls.
Latest: Bullish flow on Nov 13, $516K in unusual premium.
1of the funds Gekko tracks holds ARWR.
Arrowhead Pharmaceuticals reports on Feb 4, 2027, after the close (81 days away), and beat the EPS estimate in 3 of its last 8 reports.
Feb 4, 2027
Expected after the close, 81 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 12, 2026 | −$3.04 est −$1.52 | $37.79M est $61.18M | −3.2% |
| Aug 4, 2026 | −$1.36 est −$1.23 | $75.25M est $44.17M | +1.0% |
| May 7, 2026 | −$0.93 est −$1.11 | $73.74M est $73.84M | −8.2% |
| Feb 5, 2026 | $0.22 est −$0.37 | $264.0M est $213.9M | −5.2% |
| Nov 25, 2025 | −$0.18 est −$0.11 | $256.5M est $175.3M | +30.4% |
| Aug 7, 2025 | −$1.26 est −$0.94 | $27.77M est $154.1M | +0.7% |
| May 12, 2025 | $2.75 est −$0.46 | $542.7M est $116.3M | +17.3% |
| Feb 10, 2025 | −$1.39 est −$0.72 | $2.50M est $19.05M | −6.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Arrowhead Pharmaceuticals is $107.71, +125.4% from the last close, from 12 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 12 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | UBS | $109 | +128.1% |
| Nov 13 | Stifel Nicolaus | $96 | +100.9% |
| Nov 13 | RBC Capital | $100 | +109.3% |
| Nov 13 | Piper Sandler | $126 | +163.7% |
| Nov 13 | Morgan Stanley | $106 | +121.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Arrowhead Pharmaceuticals averaged +13.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.3% | 2 of 5 |
| Next 10 trading days | +12.0% | 4 of 5 |
| Next 15 trading days | +12.4% | 3 of 5 |
| Next 20 trading days | +13.9% | 3 of 5 |
| Next 30 trading days | +15.7% | 4 of 5 |
For scale, ARWR’s typical 20-trading-day move in either direction is about 11.1%.
Arrowhead Pharmaceuticals’s market cap is $6.75B and revenue of $669.5M over the last twelve months.
Coverage of Arrowhead Pharmaceuticals this week reads neutral: 3 positive, 5 neutral and 1 negative headlines.
Arrowhead Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Arrowhead Pharmaceuticals’s market cap is $6.75B at the Nov 13, 2026 close of $47.78, with 141.3M shares outstanding.
The consensus analyst 12-month price target for Arrowhead Pharmaceuticals is $107.71, +125.4% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Arrowhead Pharmaceuticals is undervalued: the Nov 13, 2026 close of $47.78 is 39.4% below Gekko Fair Value of $78.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Arrowhead Pharmaceuticals is expected to report on Feb 4, 2027, after the market closes (81 days away). Analysts expect earnings of −$1.45 per share on revenue of $44.96M. Arrowhead Pharmaceuticals beat the earnings estimate in 3 of its last 8 reports, moving 9.1% on average across the report.
Arrowhead Pharmaceuticals’s 52-week high is $95.49 and its 52-week low is $37.06; it closed at $47.78 on Nov 13, 2026, +15.4% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Arrowhead Pharmaceuticals over the last 30 days, with $501K of flagged premium in calls and $14K in puts. The latest, bullish flow, was on Nov 13, 2026 with $516K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.